Ricky Goldwasser
Stock Analyst at Morgan Stanley
(4.10)
# 462
Out of 5,170 analysts
233
Total ratings
60.87%
Success rate
8.36%
Average return
Main Sectors:
Stocks Rated by Ricky Goldwasser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNC Centene | Maintains: Equal-Weight | $38 → $45 | $36.61 | +22.92% | 15 | Mar 4, 2026 | |
| DOCS Doximity | Maintains: Overweight | $65 → $49 | $24.83 | +97.38% | 12 | Feb 6, 2026 | |
| UNH UnitedHealth Group | Maintains: Overweight | $411 → $409 | $284.45 | +43.79% | 21 | Jan 23, 2026 | |
| CRL Charles River Laboratories International | Maintains: Equal-Weight | $170 → $185 | $157.87 | +17.19% | 23 | Nov 11, 2025 | |
| LH Labcorp Holdings | Maintains: Overweight | $283 → $306 | $267.21 | +14.52% | 17 | Jul 25, 2025 | |
| LFST LifeStance Health Group | Reiterates: Overweight | $10 | $6.45 | +55.04% | 8 | Apr 22, 2024 | |
| GDRX GoodRx Holdings | Maintains: Equal-Weight | $8 → $5.5 | $2.16 | +155.22% | 9 | Nov 10, 2023 | |
| OSCR Oscar Health | Maintains: Equal-Weight | $5 → $7.5 | $13.54 | -44.61% | 6 | Aug 30, 2023 | |
| ALHC Alignment Healthcare | Maintains: Overweight | $19 → $12 | $18.69 | -35.78% | 8 | Aug 30, 2023 | |
| DGX Quest Diagnostics | Reiterates: Equal-Weight | $145 | $196.22 | -26.10% | 17 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $365 | $148.03 | +146.57% | 7 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $403 → $420 | $932.59 | -54.96% | 27 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $120 | $5.55 | +2,062.16% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $549 → $620 | $171.65 | +261.20% | 11 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $485 → $500 | $297.28 | +68.19% | 2 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $124 | $73.02 | +69.82% | 9 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $296 → $318 | $266.63 | +19.27% | 11 | Aug 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $70 | $213.25 | -67.17% | 17 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $182 → $195 | $167.92 | +16.13% | 6 | Oct 21, 2020 |
Centene
Mar 4, 2026
Maintains: Equal-Weight
Price Target: $38 → $45
Current: $36.61
Upside: +22.92%
Doximity
Feb 6, 2026
Maintains: Overweight
Price Target: $65 → $49
Current: $24.83
Upside: +97.38%
UnitedHealth Group
Jan 23, 2026
Maintains: Overweight
Price Target: $411 → $409
Current: $284.45
Upside: +43.79%
Charles River Laboratories International
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $170 → $185
Current: $157.87
Upside: +17.19%
Labcorp Holdings
Jul 25, 2025
Maintains: Overweight
Price Target: $283 → $306
Current: $267.21
Upside: +14.52%
LifeStance Health Group
Apr 22, 2024
Reiterates: Overweight
Price Target: $10
Current: $6.45
Upside: +55.04%
GoodRx Holdings
Nov 10, 2023
Maintains: Equal-Weight
Price Target: $8 → $5.5
Current: $2.16
Upside: +155.22%
Oscar Health
Aug 30, 2023
Maintains: Equal-Weight
Price Target: $5 → $7.5
Current: $13.54
Upside: -44.61%
Alignment Healthcare
Aug 30, 2023
Maintains: Overweight
Price Target: $19 → $12
Current: $18.69
Upside: -35.78%
Quest Diagnostics
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $145
Current: $196.22
Upside: -26.10%
Jul 14, 2023
Reiterates: Overweight
Price Target: $365
Current: $148.03
Upside: +146.57%
Jan 6, 2023
Maintains: Overweight
Price Target: $403 → $420
Current: $932.59
Upside: -54.96%
Jan 6, 2023
Maintains: Overweight
Price Target: $140 → $120
Current: $5.55
Upside: +2,062.16%
Oct 31, 2022
Maintains: Overweight
Price Target: $549 → $620
Current: $171.65
Upside: +261.20%
Oct 21, 2022
Maintains: Equal-Weight
Price Target: $485 → $500
Current: $297.28
Upside: +68.19%
Oct 11, 2022
Maintains: Overweight
Price Target: $127 → $124
Current: $73.02
Upside: +69.82%
Aug 17, 2022
Maintains: Overweight
Price Target: $296 → $318
Current: $266.63
Upside: +19.27%
Jul 14, 2022
Maintains: Overweight
Price Target: $74 → $70
Current: $213.25
Upside: -67.17%
Oct 21, 2020
Maintains: Overweight
Price Target: $182 → $195
Current: $167.92
Upside: +16.13%